| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Retina and Optic Nerve Research Laboratory, and the 2Departments of Ophthalmology, 3Physiology and Biophysics, and 4Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada; the 5Centre for Ophthalmology and Visual Science, Lions Eye Institute, University of Western Australia, Nedlands, Australia; and the 6Departments of Physiology and 7Clinical Pharmacology, University of Vienna Medical School, Vienna, Austria.
PURPOSE. To describe a model of chronic endothelin (ET)-1 administration to the optic nerve and evaluate its effect on retinal ganglion cell (RGC) and axon survival in rat.
METHODS. Osmotic minipumps were surgically implanted in one eye of 113 Brown Norway rats to deliver 0.05, 0.10, 0.20, or 0.40 µg ET-1 per day (3.3, 6.7, 13.4, and 26.8 µM, respectively), or balanced salt solution (BSS) to the immediate retrobulbar optic nerve; the fellow untreated eye served as the control. Before pump implantation, RGCs were retrogradely labeled with fluorochrome. Animals were killed at 21, 42, or 84 days. RGC survival was expressed as the ratio of RGC counts in experimental versus control eyes in wholemounted retinas, whereas axon survival was expressed similarly from electron micrographs of the optic nerves. Serial optic disc changes were evaluated using scanning laser tomography. The effect of ET-1 (3 µL topical application of 10-5 M) on blood flow in the surgically exposed optic nerve was measured using laser Doppler flowmetry in a separate group of five animals.
RESULTS. ET-1 led to a mean reduction in optic nerve blood flow of 68%. There were no significant differences in RGC survival among the four ET-1 doses used in this study. Pooled across all ET-1 doses, RGC survival decreased incrementally at 21, 42, and 84 days (P < 0.001; mean ± SD, 0.77 ± 0.25, 0.60 ± 0.27, and 0.50 ± 0.26, respectively) and was statistically significantly lower at each time point than in the BSS-treated animals. The axon survival data also showed a similar time-dependent loss. Only one of 21 animals showed significantly increased disc cupping, and there was no relationship between RGC survival and change in cupping.
CONCLUSIONS. Chronic administration of ET-1 to the rat optic nerve results in a time-dependent loss of RGCs and their axons without apparent change in optic disc topography.
This article has been cited by other articles:
|
|
 |
|
  H. Resch, K. Karl, G. Weigert, M. Wolzt, A. Hommer, L. Schmetterer, and G. Garhofer Effect of Dual Endothelin Receptor Blockade on Ocular Blood Flow in Patients with Glaucoma and Healthy Subjects Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bosco, D. M. Inman, M. R. Steele, G. Wu, I. Soto, N. Marsh-Armstrong, W. C. Hubbard, D. J. Calkins, P. J. Horner, and M. L. Vetter Reduced Retina Microglial Activation and Improved Optic Nerve Integrity with Minocycline Treatment in the DBA/2J Mouse Model of Glaucoma Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1437 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, W. H. Baldridge, and B. C. Chauhan Acute Endothelin-1 Application Induces Reversible Fast Axonal Transport Blockade in Adult Rat Optic Nerve Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 961 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. He, G. Prasanna, and T. Yorio Endothelin-1-Mediated Signaling in the Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Astrocytes Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3737 - 3745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Orgul Blood flow in glaucoma Br. J. Ophthalmol., January 1, 2007; 91(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
T. Higashide, I. Kawaguchi, S. Ohkubo, H. Takeda, and K. Sugiyama In vivo imaging and counting of rat retinal ganglion cells using a scanning laser ophthalmoscope. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2943 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Henry, D. E. Newby, D. J. Webb, P. W. F. Hadoke, and C. J. O'Brien Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2528 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Chauhan, T. L. LeVatte, K. L. Garnier, F. Tremblay, I.-H. Pang, A. F. Clark, and M. L. Archibald Semiquantitative Optic Nerve Grading Scheme for Determining Axonal Loss in Experimental Optic Neuropathy Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kobayashi, H. Oku, M. Fukuhara, S. Kojima, A. Komori, M. Ichikawa, K. Katsumura, M. Kobayashi, T. Sugiyama, and T. Ikeda Endothelin-1 Enhances Glutamate-Induced Retinal Cell Death, Possibly through ETA Receptors Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4684 - 4690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Ikram, S. de Voogd, R. C. W. Wolfs, A. Hofman, M. M. B. Breteler, L. D. Hubbard, and P. T. V. M. de Jong Retinal Vessel Diameters and Incident Open-Angle Glaucoma and Optic Disc Changes: The Rotterdam Study Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Emre, S Orgul, T Haufschild, S G Shaw, and J Flammer Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma Br. J. Ophthalmol., January 1, 2005; 89(1): 60 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Cioffi, L. Wang, B. Fortune, G. Cull, J. Dong, B. Bui, and E. M. Van Buskirk Chronic Ischemia Induces Regional Axonal Damage in Experimental Primate Optic Neuropathy Arch Ophthalmol, October 1, 2004; 122(10): 1517 - 1525. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
